Abstract
Objectives: Survey of effects on muscle for at least 3 months during statin therapy with the statin-associated muscle symstoms clinical index (SAMS-CI) in patients with acute coronary syndrome (ACS) from 08/2019 to 08/2020 at the Vietnam Heart Institute. Methods: A longitudinal follow-up study of 210 ACS patients who were given statins for 3 months, tracking muscle symptoms with a SAMS-CI scale at 1 month, 3 months, 6 months, and 12 months. Results: At 1 month and 3 months, there were 10 cases who had muscle symptoms, rate: 4,76%, but when we used SAMS-CI for these cases, the incidence of SAMS-CI ≤ 4 points is 99,52%; The incidence of SAMS-CI: 9 points in 1 cases is 0,48%; At 6 and 12 months, no cases were reported who had muscle symptoms and SAMS-CI> 4 points. SAMS-CI: 9 points were cases of moderate-grade rhabdomyolysis followed using Rosuvastatin 10mg. Conclusion: The incidence of effect on muscle in patients with ACS who received statin therapy with the SAMS-CI was low (0,48%). In cases of atypical muscle symptoms, there were no cases of an increase in the SAMS-CI score after a longitudinal follow-up of 3,6.12 months
